PARP Inhibitors in Gastric Cancer: Unlocking Precision Oncology. Read more about PARP Inhibitors in Gastric Cancer: Unlocking Precision Oncology.
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Read more about Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
A scoping review of clinical communication in cancer care in Africa. Read more about A scoping review of clinical communication in cancer care in Africa.
Metastatic insulinoma-outcomes in the current era. Read more about Metastatic insulinoma-outcomes in the current era.
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Read more about Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.
Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Read more about Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Immune-related encephalitis after immune checkpoint inhibitor therapy. Read more about Immune-related encephalitis after immune checkpoint inhibitor therapy.
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. Read more about Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Read more about Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Read more about Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
